Cargando…
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points
Background: The correlation between efficacy end points in randomized controlled trials (RCTs) of systemic therapy for non-Hodgkin's lymphoma (NHL) was investigated to identify an appropriate surrogate end point for overall survival (OS). Methods: RCTs of previously untreated NHL published from...
Autores principales: | Lee, L., Wang, L., Crump, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101365/ https://www.ncbi.nlm.nih.gov/pubmed/21266519 http://dx.doi.org/10.1093/annonc/mdq615 |
Ejemplares similares
-
Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma
por: Jiménez‐Ubieto, Ana, et al.
Publicado: (2017) -
Use of Surrogate end points in HTA
por: Mangiapane, Sandra, et al.
Publicado: (2009) -
Surrogate end points and their role in clinical trial
por: Jaykaran,
Publicado: (2009) -
Debate: Are surrogate end-point studies worth the effort?
por: Valabhji, Jonathan, et al.
Publicado: (2000) -
Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer
por: Kehl, Kenneth L., et al.
Publicado: (2021)